ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Trends in malignant mesothelioma incidence in Spain, 1999-2023: a joinpoint and age-period-cohort analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping the invisible: a Bayesian spatio-temporal analysis of male breast cancer mortality inequalities across Spanish provinces, 1999-2023.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant mesothelioma (MM) in Spain reflects historical asbestos consumption that peaked in the 1970s. Despite a 2002 ban, the absence of a national registry complicates burden estimation. We aimed to characterise incidence trends and generational risk patterns over 25 years.
methodsThis ecological study analysed Global Burden of Disease 2023 incidence data for Spain (1999-2023). Age-standardised incidence rates (ASIR) were calculated using the 2013 European Standard Population. Temporal trends were assessed via joinpoint regression. Age-period-cohort (A-P-C) modelling disentangled the independent effects of age, period, and birth cohort by sex.
resultsIn men, ASIRs increased from 1·55 to 1·94 per 100,000 (1999-2012), followed by a significant decline after 2016 (annual percentage change [APC] - 2·3%, 95% CI - 3·9- - 1·3; p < 0·001). In women, rates remained low and stable (0.45-0.50 per 100,000), with a modest increase over time (average annual percentage change 0.6%, p < 0.001). A-P-C modelling in men revealed a significant negative net drift (- 1·45% per year, p < 0·001) and strong birth cohort effects peaking in the 1944 cohort, with marked risk reduction in those born after 1964 (relative risk < 0·70). Women showed no significant cohort or period effects and minimal temporal variation.
conclusionsSpain shows evidence of a meaningful epidemiological transition in its mesothelioma epidemic. The significant decline in male incidence since 2016 is consistent with the 2002 asbestos ban and the progressive ageing-out of heavily exposed cohorts.
Indexed as
Identifiers
42332148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.